Navigation Links
Celsis Receives Frost & Sullivan 2008 Best Practices Award

CHICAGO, Oct. 1 /PRNewswire/ -- Celsis Rapid Detection, a division of Celsis International plc (LSE: CEL.L), has been named the Frost & Sullivan 2008 North American Growth Strategy Leadership Award recipient for Rapid Microbial Testing Methods used in the Manufacture and Release of Pharmaceuticals.

"The Celsis Rapid Detection system is a powerful and flexible technology that enables pharmaceutical companies to significantly reduce production cycle times in the manufacturing process," said Madhu Sharma, Ph.D, industry analyst for Frost & Sullivan. "Not only does Celsis help customers get safe products to market faster, it returns bottom-line benefits like freed-up working capital while reducing inventory and safety stock requirements."

Conventional screening for microbial contamination in raw materials, in-process work or finished goods takes an average of five days at each step. Through the use of a proprietary enzyme accelerant, the Celsis system delivers an accurate verdict in as little as 18 hours, allowing companies to run leaner and more responsive manufacturing systems.

"We are very pleased to be recognized for our leadership in rapid testing methods for pharmaceutical manufacturers," explained Jay LeCoque, Celsis CEO. "Our customers are strong advocates of rapid methods because of the highly reliable Celsis system, our world-class service, and the simple fact that we save them significant time and money by taking days out of their manufacturing cycle times."

Frost & Sullivan selected Celsis as a Best Practices Award recipient in the 2008 North American Growth Strategy Leadership category for the company's focused efforts in product innovation, sales strategy, and customer support. The research and growth consulting firm also recognized Celsis' ability to increase the market presence, regulatory acceptance, and widespread adoption of its Celsis Rapid Detection systems.

Celsis Model Identifies ROI in Advance

Frost & Sullivan cited the company's unique financial tool, the Value Creation Model (VCM), as a key initiative driving Celsis' growth. Designed in collaboration with consulting firm Arthur D. Little, Inc., the VCM calculates the financial return from implementing the Celsis system for rapid microbiological testing. According to Celsis customer data, adopters of the system see an average return on investment in six to nine months with a five-year net present value (NPV) of $500,000 for a single plant. These strong results, forecast by the VCM, encourage new customers to adopt the technology, and the tool has paved the way for Celsis to advance to the top of the market.

Additionally, as noted by Frost & Sullivan, the Celsis system is extremely flexible, the workflow is easy to learn, and the instruments and software are standardized, making it attractive to customers with multiple manufacturing facilities or various types of products. Also attractive is the company's active research and development: Celsis is devising next-generation nucleic acid technologies to position itself for long-term growth.

For more information about the Celsis system, visit, where there is a link to a free whitepaper and an online "lite" version of the Value Creation Model called the Rapid Returns calculator. Frost & Sullivan Leadership Award information is available online at

About Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers significant time and cost savings to its customers in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. Public since 1993, Celsis is headquartered in Chicago and listed on the London Stock Exchange (CEL.L).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

SOURCE Celsis International plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
Breaking Biology Technology:
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):